Skip to content

Relationships between kidney function and acute mountain sickness symptoms in healthy human adults.

Renal bicarbonate handling in acute mountain sickness in healthy human adults.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12618000548235
Enrollment
30
Registered
2018-04-12
Start date
2018-03-02
Completion date
2018-11-01
Last updated
2022-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Upon rapid ascent to high altitude, increases in breathing can induce respiratory alkalosis - an increase in blood pH. Rapid ascent is known to induce alveolar hyperventilation, where one exhales more than one inhales, increasing the ratio of expelled CO2 to O2 intake. This reduction of CO2 in the blood creates a proportional surplus of bicarbonate ions, and shifts plasma pH to more alkaline levels. In order to restore blood acid-base balance, kidneys must compensate to excrete surplus bicarbonate ions via the urine. There is evidence of correlation between urine acidity - or lack of bicarbonate clearance - and AMS symptom severity. Furthermore, Acetezolamide, a drug known to improve kidney function at high altitude, is effective at alleviating AMS. Increased blood pH is known to impair cerebral auto-regulation, increase cerebral blood flow, and degrade the blood-brain-barrier. Given the symptoms of AMS, such as dizziness, headaches, nausea, and fatigue/lassitude, and its risks, such as high-altitude cerebral oedema (brain swelling), these changes in cerebral vasculature are a logically assumed source. All this considered, it has been suggested that interpersonal differences in AMS susceptibility arise from differences in kidney function. This study aims to prove the hypothesis that kidney function, cerebral auto-regulation, and AMS symptom severity are correlated phenomena. We also hope to produce a means of extrapolating AMS risk from measures of kidney function. This will allow future identification of at-risk individuals, and even indicate an avenue of inquiry into the management of AMS. In the advent of advanced transportation, and in the face of severe medical risks and even fatality from untreated AMS, this is pertinent. The study may also provide general information on cardiovascular function and cerebral auto-regulation dynamics within whole-body integrated physiology.

Interventions

The participants will undergo two 10-hour exposure of the following conditions: 1) sea-level condition (fraction of inspired oxygen at 0.21), and 2) a simulated altitude of 5,000m (fraction of inspired oxygen around 0.12) induced in the Global Energetic and Environmental Simulation Suite (GEnESiS), in the Center for Translational Physiology at University of Otago Wellington, in a randomised, single-blinded crossover design, with one week washout period between the experimental sessions. Kidney f

The participants will undergo two 10-hour exposure of the following conditions: 1) sea-level condition (fraction of inspired oxygen at 0.21), and 2) a simulated altitude of 5,000m (fraction of inspired oxygen around 0.12) induced in the Global Energetic and Environmental Simulation Suite (GEnESiS), in the Center for Translational Physiology at University of Otago Wellington, in a randomised, single-blinded crossover design, with one week washout period between the experimental sessions. Kidney function measures will be assessed from urine output and pH during the 10 hour exposure, as well as via blood samples taken from a venous cannula to assess creatinine concentration changes every two hours. Participants will be versed in the expected effects and risks of the stimulated altitude, both in person at a 2-hour one-on-one orientation session (one week prior to the experimental sessions), and in writing at all stages of recruitment and testing. The effects of the simulated altitude will be monitored from within GEnESiS by Dr. Mickey Fan, who has a history of research in Acute Mountain Sickness since 2007. Participants will also be monitored by a clinician at all times. Over the course of the 10 hour experimental session, participants will mostly be resting in a semi-recumbent position. They will be free to stand up and walk around the chamber in between measurements.

Sponsors

Dr Jui Lin Fan
Lead SponsorIndividual

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Prevention
Masking
Blinded (masking used) (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

Healthy individuals; aged 18-45 years; free from a history of long-term disease; and not currently taking any medications that could influence the measures in the study (diuretics, antacids, proton pump inhibitors, or histamine blockers).

Exclusion criteria

Anyone who has been over 2,500m in the two months prior to testing; pregnancy; respiratory or cardiovascular diseases; specific renal impairment; currently taking diuretics, antacids, proton pump inhibitors, or histamine blockers; or a body mass index greater than 30 kg/m2. Exposure cessation criteria are an AMS score above 9 as determined by the LLQ, a resting heart rate above 140 bpm, a peripheral O2 saturation below 65%, subject intolerance or request, or mental abnormalities as assessed by a clinician (i.e.: confusion, incoordination of motor skills).

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 8, 2026